Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy

Summary

Haemorrhage, including intracranial bleeding, is a common, potentially lethal complication of warfarin therapy and rapid and complete reversal of anticoagulation may be life-saving. Fresh frozen plasma (FFP) and vitamin K are most frequently administered. Because of the variable content of vitamin K-dependent clotting factors in FFP, and the effects of dilution, the efficacy of this approach is open to doubt. We have therefore compared the effects of FFP and clotting factor concentrates on the INRs and clotting factor levels of orally anticoagulated subjects requiring rapid correction of their haemostatic defect. In many, the pre-treatment INR was considered to be dangerously above the target therapeutic range. In the 12 patients given FFP, the INR did not completely correct (range 1.6-3.8, mean 2.3) indicating an ongoing anticoagulated state in all. In contrast, the INR in 29 subjects given clotting factor concentrates was completely corrected in 28 (range 0.9-3.8, mean 1.3). Following treatment, marked differences were observed in clotting factor IX levels between the two groups. The median factor IX level was 19 u/dl (range 10-63) following FFP infusion and 68.5 u/dl (range 31-111) following concentrate. In FFP treated patients, poorer responses were also observed for each of the other vitamin K-depen- dent clotting factors but these were less marked than for factor IX, which was present in low concentrations in some batches of FFP. Thus, haemostatically effective levels of factor IX cannot be achieved, in most instances, by the conventional use of FFP in patients requiring reversal of their anticoagulant therapy. Clotting factor concentrates are the only effective option where complete and immediate correction of the coagulation defect is indicated in orally anticoagulated patients with life or limb-threatening haemorrhage.

• References

• 1 Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with Warfarin:Relation to the prothrombin time and important remedial lesions. American Journal of Medicine 1989; 87: 153-159
• 2 Wintzen AR, de JongeH, Loeliger EA, Bots GTAM. The risk of intracerebral haemorrhage during oral anticoagulant treatment:A population study. Annals of Neurology 1984; 16: 553-558
• 3 van der MeerSJM, Rosendaal FR, Van de, Broucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. Archives of Internal Medicine 1993; 153: 1557-1562
• 4 Hylek EM, Singer DE. Risk factors for intracranial haemorrhage in outpatients taking Warfarin. Annals of Internal Medicine 1994; 120: 897-902
• 5 Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Ageing and the anticoagulant response to warfarin therapy. Annals of Internal Medicine 1992; 116: 901-905
• 6 James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. Journal of Clinical Pathology 1992; 45: 704-706
• 7 Quick AJ. The prothrombin time in haemophilia and obstructive jaundice. Journal of Biological Chemistry 1935; 109: LXII-LXIV
• 8 Brettler DB, Levine PH. Clinical manifestations and therapy of inherited coagulation factor deficiencies. Haemostasis and Thrombosis 1994 In: Basic Principles and Clinical Practice. 3rd ed Colman RW, Hirsh J, Marder VJ, Salzmann EW. eds Published by J B Lippincott Co; Philadelphia USA: 169-183
• 9 Mannucci PM, Franchi F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet 1976; 542-545
• 10 Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Seminars in Haematology 1991; 28 (03) (Suppl. 06) 3-5